Zacks: Analysts Set $10.50 Price Target for Check Cap Ltd (CHEK)
Check Cap Ltd (NASDAQ:CHEK) has received a consensus broker rating score of 1.50 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company.
Brokerages have set a 1 year consensus price target of $10.50 for the company and are predicting that the company will post ($0.46) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Check Cap an industry rank of 100 out of 256 based on the ratings given to related companies.
Several equities analysts have recently commented on CHEK shares. Zacks Investment Research upgraded Check Cap from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research report on Monday, March 4th. Dougherty & Co started coverage on Check Cap in a research report on Tuesday, February 5th. They issued a “buy” rating and a $6.00 price objective on the stock.
Check Cap (NASDAQ:CHEK) last announced its quarterly earnings data on Monday, May 13th. The medical research company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.03. As a group, sell-side analysts predict that Check Cap will post -1.69 EPS for the current fiscal year.
Several institutional investors have recently made changes to their positions in CHEK. Renaissance Technologies LLC lifted its position in shares of Check Cap by 101.4% in the first quarter. Renaissance Technologies LLC now owns 247,442 shares of the medical research company’s stock valued at $668,000 after acquiring an additional 124,600 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Check Cap in the third quarter worth about $141,000. Jane Street Group LLC purchased a new stake in shares of Check Cap in the first quarter worth about $89,000. Finally, Wells Fargo & Company MN lifted its position in shares of Check Cap by 96.0% in the first quarter. Wells Fargo & Company MN now owns 9,800 shares of the medical research company’s stock worth $26,000 after buying an additional 4,800 shares in the last quarter.
Check Cap Company Profile
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Featured Article: Blockchain
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.